Slingshot Biosciences Announces Election of Nicolas Barthelemy as Executive Chair
24 Jan 2024
Executive ChangeCell Therapy
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair. “We have been working closely with Nicolas over the last two years and are excited to bring his experience, operational expertise, and strategic insights to bear on this next phase of our growth,” said Dr. Jeffrey Kim - CEO & President of Slingshot Biosciences. Dr. Kim added, “He has been a trusted partner in getting the company to where it is, today, and will continue to be a key member of our extended team as we scale the business to help patients worldwide.”
Mr. Barthelemy’s appointment comes at a crucial time as Slingshot is scaling its groundbreaking technologies in the biopharma sector, where he brings a long history of leadership in operating roles. His past experience includes Senior Management positions at leading companies in the sector, including Biogen and Life Technologies, where he held the position of Chief Commercial Officer. Nicolas also currently holds board positions at Repligen, Inc., Biocare Medical, and Nanocellect.
“I am very excited to step-up my involvement with such a talented team at a pivotal time of its journey, and at the 'ground level' of a technology as potentially disruptive as Slingshot Biosciences' novel synthetic cells. With end-applications ranging from Research and Bioprocessing to Hematology, Diagnostics and Therapeutics, we have the opportunity to build a company that could meaningfully impact a very broad area of Life Sciences,” said Nicolas Barthelemy.
Nicolas received an Engineering Degree from ESPCI (Paris, France) and an M.S. in Chemical Engineering from UC Berkeley.
About Slingshot Biosciences
At the cutting edge of cell engineering technology, Slingshot Biosciences is revolutionizing cell therapy development and manufacturing. The company’s pioneering work in creating cell mimics positions it uniquely to help advance research, diagnostics and biopharma manufacturing. Slingshot’s products offer more consistent, scalable, and ethically viable alternatives to traditional methods of cell-based sourcing.
View source version on businesswire.com:
Contacts
Annalise Barnette
pr@slingshotbio.com
Source: Slingshot Biosciences Inc.
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.